Speech-Language Pathologists in Naguabo, PR Accepting Medicare
4 Speech-Language Pathologists found. Showing 1 - 4
 Mrs. Joan Marie Sifres Negron, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: Carr 969 Km 6.5, Bo Maizales, Naguabo, PR 00718 Phone: 787-312-4266 |
Mrs. Sheilynette Robles, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 38 Munos Rivera St, Trejo Family Clinic, Naguabo, PR 00718 Phone: 787-874-3786 Fax: 787-874-3786 |
Rachel Lopez, PHL Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: Urbanizacion Villa Rosario Calle1 B-8, Naguabo, PR 00718 Phone: 787-874-3650 |
Mrs. Mariacarmina Arzon, MS SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: #87 Calle Monte De Los Olivos Urb. Promised Land, Naguabo, PR 00718 Phone: 787-605-2936 |
News Archive
UT Southwestern's Dr. Nijhawan selected for ASCI's 2018 Seldin-Smith Award
UT Southwestern's Dr. Deepak Nijhawan became a co-recipient of the 2018 Donald Seldin-Holly Smith Award for Pioneering Research. The award recognizes Dr. Nijhawan's work identifying targets for cancer treatment.
Access to genetic counseling and testing are an important part of cancer control
Ten years after the identification of the first breast cancer susceptibility genes so few high-risk minority women have received genetic counseling or testing that the standard methods of calculating risk have not been validated in these groups and the results of genetic testing can still produce surprises.
Vanda to initiate tasimelteon Phase IIb/III clinical trial in Major Depressive Disorder
Vanda Pharmaceuticals Inc. today announced its plans to initiate a Phase IIb/III clinical trial of tasimelteon in patients with Major Depressive Disorder (MDD). The trial is expected to begin during the second half of 2011. Tasimelteon is currently being evaluated in Phase III clinical trials for the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals without light perception.
New combination of antibodies leads to more effective tumor destruction
The simultaneous use of antibodies based on two differing mechanisms of action leads to a more effective destruction of tumors.
Study compares NAbs from natural SARS-CoV-2 infection vs. vaccine induced against symptomatic infection
Scientists have recently compared the levels of antibody concentrations in unvaccinated, SARS-CoV-2 convalescent individuals and COVID-19 specific antibodies in vaccinated individuals.
› Verified 6 days ago
Speech-Language Pathologists
Optometrists
Physical Therapists
Occupational Therapists